Nevro Corp Stock Today
NVRO Stock | USD 5.80 0.01 0.17% |
PerformanceOK
| Odds Of DistressAverage
|
Nevro Corp is selling at 5.80 as of the 17th of March 2025; that is 0.17% increase since the beginning of the trading day. The stock's open price was 5.79. Nevro Corp has 51 percent odds of going through some form of financial distress in the next two years but had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 6th of November 2014 | Category Healthcare | Classification Health Care |
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California. Nevro Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. The company has 38.37 M outstanding shares of which 1.82 M shares are now shorted by private and institutional investors with about 1.14 trading days to cover. More on Nevro Corp
Moving together with Nevro Stock
Moving against Nevro Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Nevro Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
CEO President | Kevin Thornal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, Medical Equipment, Obamacare Repeal, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNevro Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nevro Corp's financial leverage. It provides some insight into what part of Nevro Corp's total assets is financed by creditors.
|
Nevro Corp (NVRO) is traded on New York Stock Exchange in USA. It is located in 1800 Bridge Parkway, Redwood City, CA, United States, 94065 and employs 1,099 people. Nevro Corp is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 222.56 M. Nevro Corp conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 38.37 M outstanding shares of which 1.82 M shares are now shorted by private and institutional investors with about 1.14 trading days to cover.
Nevro Corp currently holds about 310.82 M in cash with (19.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Nevro Corp Probability Of Bankruptcy
Ownership AllocationThe majority of Nevro Corp outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nevro Corp to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nevro Corp. Please pay attention to any change in the institutional holdings of Nevro Corp as this could imply that something significant has changed or is about to change at the company.
Check Nevro Ownership Details
Nevro Stock Institutional Holders
Instituion | Recorded On | Shares | |
State Street Corp | 2024-12-31 | 769.9 K | |
Palo Alto Investors, Llc | 2024-12-31 | 750.4 K | |
Assenagon Asset Management Sa | 2024-12-31 | 670.8 K | |
Jacobs Levy Equity Management, Inc. | 2024-12-31 | 661.7 K | |
Western Standard Llc | 2024-12-31 | 645.1 K | |
Citadel Advisors Llc | 2024-12-31 | 598.9 K | |
Jpmorgan Chase & Co | 2024-12-31 | 506.4 K | |
Goldman Sachs Group Inc | 2024-12-31 | 455.1 K | |
Jefferies Financial Group Inc | 2024-12-31 | 441.9 K | |
Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 4.4 M | |
Armistice Capital, Llc | 2024-12-31 | 3.7 M |
Nevro Corp Historical Income Statement
Nevro Stock Against Markets
Nevro Corp Corporate Directors
Elizabeth Weatherman | Independent Director | Profile | |
Brad Vale | Independent Director | Profile | |
Kevin OBoyle | Independent Director | Profile | |
Shawn McCormick | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.06) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.